Compare ETON & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETON | PNNT |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.7M | 285.3M |
| IPO Year | 2018 | 2007 |
| Metric | ETON | PNNT |
|---|---|---|
| Price | $26.93 | $4.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $39.33 | $5.85 |
| AVG Volume (30 Days) | 465.8K | ★ 747.6K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 20.87% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $40.90 | N/A |
| Revenue Next Year | $47.23 | N/A |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $13.09 | $4.29 |
| 52 Week High | $27.19 | $7.53 |
| Indicator | ETON | PNNT |
|---|---|---|
| Relative Strength Index (RSI) | 73.61 | 45.43 |
| Support Level | $16.23 | N/A |
| Resistance Level | N/A | $4.69 |
| Average True Range (ATR) | 1.16 | 0.13 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 99.79 | 67.92 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.